Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home ItemIn Person Seminar: Deciphering the Metabolic Origins of Heart Failure: Towards Novel Therapeutic Targets , home
March 22, 2024, 11 a.m. | Daniel Kelly, Ph.D., Willard and Rhoda Ware Professor, Director, Penn and CHOP Cardiovascular Institutes, Perelman School of Medicine, University of Pennsylvania and Children's Hospital of Philadelphia | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home ItemCANCELLED: In Person Seminar: Circadian Clocks in Skeletal Muscle; Contributions to Systemic Health , home
March 29, 2024, 11:00 a.m. | Karyn Esser, Ph.D., Professor and Chair, Physiology and Aging, University of Florida College of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home ItemThe Impact of Climate Change on Vulnerable Populations: What Can Be Done? , home
April 4, 2024, 5:30 p.m. (Reception at 5 p.m.) | Zulfiqar Bhutta, Ph.D., Robert Harding Inaugural Chair in Global Child Health, Hospital for Sick Children, Professor, Department of Paediatrics, Nutritional Sciences and Public Health, University of Toronto | Maury Strauss Distinguished Public Lecture
-
Home ItemIn Person Seminar: The Meaning of Dopamine , home
April 5, 2024, 11:00 a.m. | Henry Yin, Ph.D., Professor, Psychology and Neuroscience, Duke University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home ItemWhat is Alzheimer's Disease and Can We Prevent It? , home
April 11, 2024, 5:30 p.m. (Reception at 5 p.m.) | Kristine Yaffe, M.D., Professor and Roy and Marie Scola Endowed Chair of Psychiatry, Neurology, and Epidemiology, Director, Center for Population Brain Health, University of California, San Francisco, Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home ItemIn Person Seminar: Addiction Recovery: From Culture to Science , home
April 12, 2024, 11:00 a.m. | John Kelly, Ph.D., Elizabeth R. Spallin Professor of Psychiatry in Addiction Medicine, Harvard Medical School | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and the Addiction Recovery Research Center